Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 1. Age-specific prevalence of dengue immunoglobulin G (IgG) in serological samples collected in Singapore in ... Figure 1. Age-specific prevalence.

Published byGunnar Åström Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure 1. Age-specific prevalence of dengue immunoglobulin G (IgG) in serological samples collected in Singapore in ... Figure 1. Age-specific prevalence."— Presentation transcript:

1 Figure 1. Age-specific prevalence of dengue immunoglobulin G (IgG) in serological samples collected in Singapore in ... Figure 1. Age-specific prevalence of dengue immunoglobulin G (IgG) in serological samples collected in Singapore in 2013 (A) and 2017 (B). The presence of dengue IgG in the serum samples was determined using the Panbio Dengue IgG Indirect ELISA (Alere Inc., Waltham, Massachusetts). Confidence intervals (black bars) were constructed using Wald's method. Participants aged 66 years or more were combined into one group because of the small sample size. ELISA, enzyme-linked immunosorbent assay. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact American Journal of Epidemiology, Volume 188, Issue 8, 07 May 2019, Pages 1529–1538, The content of this slide may be subject to copyright: please see the slide notes for details.

2 Figure 2. Estimated annual dengue force of infection (FOI) in Singapore during the periods 1931–2017 (A) and 1990– Figure 2. Estimated annual dengue force of infection (FOI) in Singapore during the periods 1931–2017 (A) and 1990–2015 (B). An overall declining trend in FOI estimates was observed from 1931 to 2017 (A); however, the FOI estimates increased slightly from 1999 to 2008 and then decreased (B). Solid lines represent the point estimates, and shaded regions represent the 95% Bayesian credible intervals. The model was developed using 2004, 2009, 2013, and 2017 serosurvey data. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact American Journal of Epidemiology, Volume 188, Issue 8, 07 May 2019, Pages 1529–1538, The content of this slide may be subject to copyright: please see the slide notes for details.

3 Figure 3. Comparison of empirical and reconstructed prevalences of dengue immunoglobulin G from independent serosurveys ... Figure 3. Comparison of empirical and reconstructed prevalences of dengue immunoglobulin G from independent serosurveys carried out in Singapore in 2004, 2009, 2013, and Empirical estimates are shown as black dots and 95% Clopper-Pearson confidence intervals by black bars. Solid gray lines represent the model estimates for 2004 (A), 2009 (B), 2013 (C), and 2017 (D), with the gray shaded regions representing 95% Bayesian credible intervals. Degradation of the sensitivity of the enzyme-linked immunosorbent assay over time was taken into account in the reconstructed estimates. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact American Journal of Epidemiology, Volume 188, Issue 8, 07 May 2019, Pages 1529–1538, The content of this slide may be subject to copyright: please see the slide notes for details.

4 Figure 4. Dengue seroprevalence by age and year among residents of Singapore, generated with Bayesian modeling, 2009, ... Figure 4. Dengue seroprevalence by age and year among residents of Singapore, generated with Bayesian modeling, 2009, 2013, and Lines represent posterior median values for seroprevalence, and shaded areas represent 95% Bayesian credible intervals. A) Seroprevalence in the years 2009, 2013, and 2017 based on age in Within each birth cohort, only a marginal increase in seroprevalence is observable from 2009 to 2013 and from 2013 to The gap is most prominent in the youngest age group. B) Seroprevalence in the years 2009, 2013, and 2017 based on age in 2009, 2013, and 2017, respectively. Holding age fixed (in 2009, 2013, and 2017), the estimated prevalence for persons over age 23 years was lower in 2013 than in 2009 and lower in 2017 than in 2013. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact American Journal of Epidemiology, Volume 188, Issue 8, 07 May 2019, Pages 1529–1538, The content of this slide may be subject to copyright: please see the slide notes for details.

5 Figure 5. Estimated annual basic reproduction number (R0) for dengue (A) and reconstructed annual dengue ... Figure 5. Estimated annual basic reproduction number (R<sub>0</sub>) for dengue (A) and reconstructed annual dengue seroprevalence (B) in Singapore, 1960–2020. Solid lines represent the point estimates, and shaded regions represent 95% Bayesian credible intervals. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact American Journal of Epidemiology, Volume 188, Issue 8, 07 May 2019, Pages 1529–1538, The content of this slide may be subject to copyright: please see the slide notes for details.

6 Figure 6. Estimated age-specific dengue seroprevalence in Singapore in 2017, modeled from 4 hypothetical circumstances: ... Figure 6. Estimated age-specific dengue seroprevalence in Singapore in 2017, modeled from 4 hypothetical circumstances: force of infection (FOI) fixed at the 1960s, 1970s, 1980s, and 1990s averages, respectively. The black line represents the age-specific seroprevalence in 2017 based on the original FOI estimates. Of the 4 hypothetical situations, the largest number of dengue infections averted occurs when the FOI is held fixed at the 1960s average (3.12 million; 95% Bayesian credible interval (BCrI): 2.94, 3.27), assuming that numbers of primary and subsequent dengue infections are similar. For scenarios where FOI is held fixed at the 1970s, 1980s, and 1990s averages, the numbers of dengue infections averted are estimated to be 1.90 million (95% BCrI: 1.63, 2.14), 0.87 million (95% BCrI: 0.61, 1.13), and −0.11 million (95% BCrI: −0.30, 0.07), respectively. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact American Journal of Epidemiology, Volume 188, Issue 8, 07 May 2019, Pages 1529–1538, The content of this slide may be subject to copyright: please see the slide notes for details.

Download ppt "Figure 1. Age-specific prevalence of dengue immunoglobulin G (IgG) in serological samples collected in Singapore in ... Figure 1. Age-specific prevalence."

Similar presentations

From: Learning by Working in Big Cities

From: Learning by Working in Big Cities
Fig. 1 Nodes in a conceptual knowledge graph

Fig. 1 Nodes in a conceptual knowledge graph
Figure 1. The flow chart illustrates the construction process of anti-CRISPRdb, and the information that users can obtain from anti-CRISPRdb. From: Anti-CRISPRdb:

Figure 1. The flow chart illustrates the construction process of anti-CRISPRdb, and the information that users can obtain from anti-CRISPRdb. From: Anti-CRISPRdb:
Figure 1: Necrobiosis lipoidica: Yellow-brown skin lesions with indurated borders located on both lower legs. Figure 1: Necrobiosis lipoidica: Yellow-brown.

Figure 1: Necrobiosis lipoidica: Yellow-brown skin lesions with indurated borders located on both lower legs. Figure 1: Necrobiosis lipoidica: Yellow-brown.
Figure 1. Circular taxonomy tree based on the species that were sequenced in our study. Unless provided in the caption above, the following copyright applies.

Figure 1. Circular taxonomy tree based on the species that were sequenced in our study. Unless provided in the caption above, the following copyright applies.
ADAb: anti-drug antibody.

ADAb: anti-drug antibody.
Figure 1 Hazard ratios as a function of annual mean PM2

Figure 1 Hazard ratios as a function of annual mean PM2
Figure 1 Schematic representation of the extreme SVD design in the 3C-Dijon study. Unless provided in the caption above, the following copyright applies.

Figure 1 Schematic representation of the extreme SVD design in the 3C-Dijon study. Unless provided in the caption above, the following copyright applies.
Figure 1 The study area within Vienna Zoo is outlined in red

Figure 1 The study area within Vienna Zoo is outlined in red
Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.
Figure 1: Axial T2 W images of penis showed a well-defined septated area of 2 cm in the posterior aspect of ... Figure 1: Axial T2 W images.

Figure 1: Axial T2 W images of penis showed a well-defined septated area of 2 cm in the posterior aspect of ... Figure 1: Axial T2 W images.
Figure 1 Data-selection process

Figure 1 Data-selection process
FIGURE 1 Histological diagnoses divided into 8-year time frames (n = 1208). Unless provided in the caption above, the following copyright applies to the.

FIGURE 1 Histological diagnoses divided into 8-year time frames (n = 1208). Unless provided in the caption above, the following copyright applies to the.
FIGURE 1 The effect of daprodustat on hemoglobin (Hgb) levels

FIGURE 1 The effect of daprodustat on hemoglobin (Hgb) levels
FIGURE 2 Responses to the question: regarding vasoactive drugs, does your centre use the following frequently, rarely ... FIGURE 2 Responses to the question:

FIGURE 2 Responses to the question: regarding vasoactive drugs, does your centre use the following frequently, rarely ... FIGURE 2 Responses to the question:
FIGURE 1 Maternal (A) urinary aldosterone; (B) plasma active renin; (C) urinary AGT concentrations; and (D) plasma AGT ... FIGURE 1 Maternal (A) urinary.

FIGURE 1 Maternal (A) urinary aldosterone; (B) plasma active renin; (C) urinary AGT concentrations; and (D) plasma AGT ... FIGURE 1 Maternal (A) urinary.
FIGURE 1 Flow chart of patient enrollment and exclusion

FIGURE 1 Flow chart of patient enrollment and exclusion
Figure 1. Ratios of observed to expected numbers of exon boundaries aligning to boundaries of domain and disorder ... Figure 1. Ratios of observed to expected.

Figure 1. Ratios of observed to expected numbers of exon boundaries aligning to boundaries of domain and disorder ... Figure 1. Ratios of observed to expected.
Figure 1. Multivariable-adjusted hazard ratios (solid line) for incident chronic obstructive pulmonary disease as a ... Figure 1. Multivariable-adjusted.

Figure 1. Multivariable-adjusted hazard ratios (solid line) for incident chronic obstructive pulmonary disease as a ... Figure 1. Multivariable-adjusted.
Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Similar presentations

Ads by Google